We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Lipid Cutoffs Identified for CVD Risk in Young Adults Without Diabetes

By LabMedica International staff writers
Posted on 09 Aug 2022
Print article
Image: Lipid cutoffs defined for increased cardiovascular disease risk in non-diabetic young people (Photo courtesy of Dreamstime)
Image: Lipid cutoffs defined for increased cardiovascular disease risk in non-diabetic young people (Photo courtesy of Dreamstime)

The underlying pathogenesis and progression associated with nearly all cardiovascular diseases (CVDs) are predominantly of atherosclerotic origin that leads to the development of coronary artery disease, cerebrovascular disease, venous thromboembolism and, peripheral vascular disease, subsequently causing myocardial infarction (MI), cardiac arrhythmias or stroke.

The etiological risk factors leading to the onset of CVDs are well recognized and include hyperlipidemia, hypertension, diabetes, obesity, smoking and, lack of physical activity. They collectively represent more than 90% of the CVD risks in all epidemiological studies. Despite high fatality rate of CVDs, the identification and careful prevention of the underlying risk factors can significantly reduce the global epidemic of CVDs.

Endocrinologists at the Yeouido St. Mary’s Hospital (Seoul, South Korea) used data from the nationally representative Korean National Health Insurance System database to identify lipid cutoffs associated with increased risk for CVD among adults aged 20 to 39 years without diabetes. The analysis consisted of 6,204,153 young adults who underwent health examinations from 2009 to 2012 and followed until the end of 2018. The primary outcome was incident CVD, defined as MI and stroke. 

The investigators reported that during a median follow-up of 7.7 years, there were 14,569 (0.23%) cases of myocardial infarction, 9,459 (0.15%) cases of stroke, and 23,680 (0.38%) cases of composite CVD. Using total cholesterol (TC) level of <140 mg/dL, triglyceride (TG) level of <60 mg/dL, LDL-cholesterol level of <100 mg/dL, and non-HDL-cholesterol level of <130 mg/dL as reference groups, a significantly higher risk of CVD was observed in subjects with a TC level of ≥200 mg/dL, TG level of ≥60 mg/dL, LDL-cholesterol level of ≥130 mg/dL, or non-HDL-cholesterol level of ≥140 mg/dL. The cutoff levels of TC that had statistical significance for increased risk of CVD were 240, 220, and 200 mg/dL in subjects with 0, 1, or 2–3 risk factors, respectively.

Mee Kyoung Kim, MD, PhD, the senior author of the study, said, “Considerable uncertainty exists about the extent to which slightly increased cholesterol levels affect long-term cardiovascular risk and about which cutoff should be used to merit a treatment recommendation in young people. Our study extends the current knowledge because it suggests that even slightly increased concentrations of total cholesterol, LDL-C, non-HDL-C and triglycerides may predict long-term cardiovascular risk in young populations.”

The authors concluded that at present, calculated risk is one of the primary criteria adopted by guidelines to initiate lipid-lowering therapy to reduce the subsequent risk of CVD. Because age is the principal determinant used in risk engines or guideline algorithms, lipid-lowering interventions become common only after 60 years of age except for those with markedly elevated LDL-C levels or diabetes. Although the 10-year risk is low in young and middle-aged adults who are not treated according to current guidelines, they ultimately account for most incident of Atherosclerotic Cardiovascular Disease (ASCVD) cases.” The final version of the study was published on July 27, 2022 in the journal European Journal of Preventive Cardiology.

Related Links:
Yeouido St. Mary’s Hospital

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Blood Gas and Chemistry Analysis System
Edan i500
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.